Literature DB >> 17697964

Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.

Nancy M Hardy1, Frances Hakim, Seth M Steinberg, Michael Krumlauf, Romana Cvitkovic, Rebecca Babb, Jeanne Odom, Daniel H Fowler, Ronald E Gress, Michael R Bishop.   

Abstract

Mixed chimerism in the T cell compartment (MCT) after reduced-intensity stem cell transplantation (RIST) may influence immune repopulation with alloreactive donor T cells. We examined effects of host T cell numbers on donor T cell engraftment and recovery and on acute graft-versus-host disease (aGVHD) in a relatively homogeneous patient population with respect to residual host T cells through quantified immune depletion prior to RIST and to donor T cells by setting the allograft T cell dose of 1x10(5) CD3+ cells/kg. In this setting, 2 patterns of early donor T cell engraftment could be distinguished by day +42: (1) early and complete donor chimerism in the T cell compartment (FDCT) and (2) persistent MCT. FDCT was associated with lower residual host CD8+ T cell counts prior to transplant and aGVHD. With persistent MCT, subsequent development of aGVHD could be predicted by the direction of change in T cell donor chimerism after donor lymphocyte infusion, and no aGVHD occurred until FDCT was established. MCT did not affect recovery of donor T cell counts. These observations suggest that the relative number and alloreactivity of donor and host T cells are more important than the absolute allograft T cell dose in determining donor engraftment and aGVHD after RIST.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697964      PMCID: PMC2699412          DOI: 10.1016/j.bbmt.2007.05.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  29 in total

Review 1.  Mixed hematopoietic chimerism for the simultaneous induction of T and B cell tolerance.

Authors:  Megan Sykes; Ichiro Shimizu; Toshiyasu Kawahara
Journal:  Transplantation       Date:  2005-02-15       Impact factor: 4.939

2.  Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism.

Authors:  Jonathan D Powell; Courtney Fitzhugh; Elizabeth M Kang; Mathew Hsieh; Ronald H Schwartz; John F Tisdale
Journal:  Transplantation       Date:  2005-12-15       Impact factor: 4.939

3.  Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.

Authors:  B D Johnson; E E Becker; R L Truitt
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

4.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

5.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

6.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.

Authors:  A J Barrett; D Mavroudis; J Tisdale; J Molldrem; E Clave; C Dunbar; M Cottler-Fox; S Phang; C Carter; P Okunnieff; N S Young; E J Read
Journal:  Bone Marrow Transplant       Date:  1998-03       Impact factor: 5.483

7.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells.

Authors:  W D Shlomchik; M S Couzens; C B Tang; J McNiff; M E Robert; J Liu; M J Shlomchik; S G Emerson
Journal:  Science       Date:  1999-07-16       Impact factor: 47.728

8.  Reconstitution of the lymphocyte compartment after lymphocyte depletion: a key issue in clinical immunology.

Authors:  Frances T Hakim; Ronald E Gress
Journal:  Eur J Immunol       Date:  2005-11       Impact factor: 5.532

9.  Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Frédéric Baron; Jennifer E Baker; Rainer Storb; Theodore A Gooley; Brenda M Sandmaier; Michael B Maris; David G Maloney; Shelly Heimfeld; Dmitrij Oparin; Eustacia Zellmer; Jerald P Radich; F Carl Grumet; Karl G Blume; Thomas R Chauncey; Marie-Térèse Little
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

10.  Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts.

Authors:  E Roux; C Helg; F Dumont-Girard; B Chapuis; M Jeannet; E Roosnek
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

View more
  5 in total

1.  Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.

Authors:  Amir A Toor; Roy T Sabo; Harold M Chung; Catherine Roberts; Rose H Manjili; Shiyu Song; David C Williams; Wendy Edmiston; Mandy L Gatesman; Richard W Edwards; Andrea Ferreira-Gonzalez; William B Clark; Michael C Neale; John M McCarty; Masoud H Manjili
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

2.  Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.

Authors:  Nancy M Hardy; Miriam E Mossoba; Seth M Steinberg; Vicki Fellowes; Xiao-Yi Yan; Frances T Hakim; Rebecca R Babb; Daniele Avila; Juan Gea-Banacloche; Claude Sportès; Bruce L Levine; Carl H June; Hahn M Khuu; Ashley E Carpenter; Michael C Krumlauf; Andrew J Dwyer; Ronald E Gress; Daniel H Fowler; Michael R Bishop
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

3.  Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.

Authors:  Kristin Baird; Terry J Fry; Seth M Steinberg; Michael R Bishop; Daniel H Fowler; Cynthia P Delbrook; Jennifer L Humphrey; Alison Rager; Kelly Richards; Alan S Wayne; Crystal L Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-05       Impact factor: 5.742

4.  Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.

Authors:  Miriam E Mossoba; Masanori Onda; Justin Taylor; Paul R Massey; Shirin Treadwell; Elad Sharon; Raffit Hassan; Ira Pastan; Daniel H Fowler
Journal:  Clin Cancer Res       Date:  2011-04-26       Impact factor: 12.531

5.  The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.

Authors:  Rohtesh S Mehta; Antonio Di Stasi; Borje S Andersson; Yago Nieto; Roy Jones; Marcos de Lima; Chitra Hosing; Uday Popat; Partow Kebriaei; Betul Oran; Amin Alousi; Katayoun Rezvani; Muzaffar Qazilbash; Qaiser Bashir; Catherine Bollard; Laurence Cooper; Laura Worth; Priti Tewari; Ian McNiece; Kaci Willhelm; Richard Champlin; Elizabeth J Shpall
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-10-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.